
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Psychiatric Times revisits some meaningful reflections on Thanksgiving, family traditions, and the value of gratitude and thankfulness.




